Initial public offering of BioArctic AB (SE) on Nasdaq Stockholm – SEK 805 million

Carnegie acted as sole global co-ordinator and joint bookrunner in the initial public offering of BioArctic on Nasdaq Stockholm. BioArctic develops disease-modifying treatments based on monoclonal antibodies for the treatment of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and has a potential treatment for complete spinal cord injury currently in clinical phase. October 2017.